Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

5.740 +0.290 (+5.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Amylyx Pharmaceuticals - An Emerging Leader In ALS
Amylyx has sold off from its earnings report on March 13th. What has been driving this move and what does it mean for the long term prospects of Amylyx? 
Via Talk Markets
Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
7 Biotech Stocks to Buy for 100% Returns
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
Analyst Ratings for Amylyx Pharma
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
Via Benzinga
Expert Ratings for Amylyx Pharma
Via Benzinga
Looking Into Amylyx Pharmaceuticals's Return On Capital Employed
Via Benzinga
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
A market rally is underway, but bank stocks kept tumbling. 
Via Investor's Business Daily
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a... 
Via Benzinga
Analyst Expectations for Amylyx Pharma's Future
Via Benzinga
Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today
The biopharma's new ALS drug is exceeding projections on the sales front. 
Via The Motley Fool
Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment
Analysts saw just $4.7 million in sales of Relyvrio. Amylyx blew that out of the water. 
Via Investor's Business Daily
First Republic Bank, PacWest Bancorp, Western Alliance Bancorporation And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday
Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on... 
Via Benzinga
Amylyx: An "Ice Bucket" Buy
The drug was green-lighted by the Food & Drug Administration last month, after clinical trials partially funded by Ice Bucket Challenge grants showed that Relyvrio takers had a median survival period... 
Via Talk Markets
Why PacWest Bancorp Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
Gainers PacWest Bancorp (NASDAQ: PACW) rose 29.9% to $12.66 in pre-market trading after multiple insider buys by Officers, Directors reported late Monday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with an overview of the biggest pre-market stock movers investors need to keep an eye on for Tuesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data
Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.  
Via Benzinga
Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles
Energy and medical plays top the 100 Best Stocks of 2022. It makes sense, given world events that shifted the first-quarter playing field. 
Via Investor's Business Daily
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.